Table 1.
Patient characteristics
| 2-D planning group | 3-D planning group | p value | |
|---|---|---|---|
| Total number, n | 346 | 332 | |
| Age at diagnosis, median (range) years | 52 (22–80) | 57 (22–88) | < 0.001 |
| Premenopausal patients, n (%) | 168 (49) | 112 (34) | < 0.001 |
| Tumor stage (pathological), n (%) | 0.1 | ||
| I | 194 (56) | 206 (62) | |
| II | 149 (43) | 121 (36) | |
| III | 3 (1) | 5 (2) | |
| Pathological size of primary tumor, median (range), cm | 2.0 (0.1–6) | 2.0 (0.1–7) | 0.09 |
| Estrogen receptor status, n (%) | 0.71 | ||
| Positive | 274 (79) | 259 (78) | |
| Negative | 72 (21) | 73 (22) | |
| Progesterone receptor, status n (%) | 0.38 | ||
| Positive | 229 (66) | 209 (63) | |
| Negative | 117 (34) | 123 (37) | |
| HER-2 overexpression, n (%) | 0.05 | ||
| Positive | 46 (13) | 28 (9) | |
| Negative | 300 (87) | 303 (91) | |
| Lymphovascular invasion, n (%) | < 0.001 | ||
| Present | 113 (33) | 229 (69) | |
| Absent | 233 (67) | 103 (31) | |
| Nuclear grade, n (%) | 0.83 | ||
| 1–2 | 304 (88) | 289 (87) | |
| ≥3 | 40 (12) | 40 (13) | |
| Histology, n (%) | 0.5 | ||
| Ductal | 313 (91) | 308 (93) | |
| Lobular | 4 (1) | 2 (1) | |
| Other | 29 (8) | 22 (7) | |
| Lymph node metastases, n (%) | < 0.001 | ||
| Unknown | 275 (79) | 37 (11) | |
| Negative by sentinel node biopsy | 71 (21) | 295 (89) | |
| Adjuvant chemotherapy, n (%) | 231 (67) | 57 (17) | < 0.001 |
| Adjuvant hormone therapy, n (%) | 140 (40) | 253 (76) | < 0.001 |
2-D = 2-dimensional; 3-D = 3-dimensional; HER-2 = human epidermal growth factor receptor 2.